Highlights

  • Vita Life Sciences (ASX:VLS) has declared a 5c per share interim dividend, franked to 60%.
  • The dividend has an ex-dividend date of 18 September 2026 and payment date of 2 October 2026.
  • The interim payment carries an annual Yield of 5.19%.
  • Vita Life combines a consumer-health growth story with an established approach to returning cash to shareholders.

Vita Life Sciences (ASX:VLS), the health-supplements and wellness group with operations across South-East Asia and Australia, has declared an Interim Dividend of 5 cents per share. The payment is franked to 60%, with an ex-dividend date of 18 September 2026, a Record Date of 21 September 2026 and payment due on 2 October 2026. The dividend carries an annual yield of 5.19%. That represents a modest lift on the 4.5 cent interim paid a year earlier, and continues the company's habit of returning cash to shareholders twice a year. Because Vita Life reports on a calendar-year basis, this September payment is an interim distribution rather than a final, and it should not be annualised on its own when assessing the stock's income profile.

The 5 cent interim is franked to 60%, so eligible Australian shareholders receive partial franking credits — the payment grosses up to roughly 6.3 cents including those credits. Investors entitled to the dividend based on the relevant record date will receive the cash on 2 October.

This is a single interim payment, typically followed by a further distribution later in the financial year, so the 5 cents should be viewed as one instalment rather than a full-year figure. Trailing 12-month dividends total around 14 cents per share, with a Payout Ratio near 76% of earnings. The lift from 4.5 to 5 cents at the interim stage points to a willingness to grow distributions in step with profitability, though the 60% franking is a reminder that a portion of Earnings is generated offshore.

What is driving the business?

Vita Life Sciences develops, markets and distributes vitamins, supplements and health and wellness products, with a significant presence in markets such as Malaysia, Singapore and Indonesia alongside Australia. Its brands are sold through pharmacies, retailers and direct channels, and the group benefits from rising consumer interest in preventative health and self-care across the region.

Growth is tied to consumer spending on discretionary health products, Brand strength, and the company's ability to expand distribution and launch new lines. Operating across multiple South-East Asian markets brings currency exposure and regulatory complexity, but it also gives Vita Life access to populations with growing middle classes and increasing health awareness. The partial franking on dividends reflects that a meaningful share of profits is earned outside Australia, where Australian franking credits are not generated.

Why income investors may be watching

Vita Life pairs a consumer-health growth story with a consistent, if partially franked, dividend. For income investors, the appeal is a small-cap that has been prepared to lift its distributions as earnings have grown, backed by cash generation from established regional brands.

The step-up from 4.5 to 5 cents at the interim will interest holders watching for dividend growth. That said, the 60% franking means the after-tax value differs from a fully franked payout, and investors may want to watch how the full-year distribution shapes up, and whether regional consumer Demand continues to support both earnings and the payout.

Risks

As a small cap with operations concentrated in South-East Asia, Vita Life carries currency risk, Regulatory Risk across several jurisdictions, and exposure to discretionary consumer spending that can soften in weaker conditions. Competition in the supplements category is intense, and shifts in consumer preferences or channel dynamics could pressure sales.

Liquidity in the shares is limited and analyst coverage is thin. The partial franking reduces the Credit benefit relative to a fully franked payer, and dividends are reviewed each period rather than guaranteed.

Investor takeaway

Vita Life Sciences' 5 cent interim dividend, franked to 60%, nudges the payout above the prior year's interim and underlines the company's steady approach to returning cash. The attraction is a regional consumer-health Business that has grown distributions alongside earnings, though the partial franking and small-cap risks temper the story. As this is only an interim payment, investors may want to watch the full-year distribution and the health of the group's key South-East Asian markets before judging the wider income case.